bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Feb. 4, 2022
Summary
SARS-CoV-2
Omicron
is
highly
transmissible
and
has
substantial
resistance
to
antibody
neutralization
following
immunization
with
ancestral
spike-matched
vaccines.
It
unclear
whether
boosting
Omicron-specific
vaccines
would
enhance
immunity
protection.
Here,
nonhuman
primates
that
received
mRNA-1273
at
weeks
0
4
were
boosted
week
41
or
mRNA-Omicron.
Neutralizing
titers
against
D614G
4760
270
reciprocal
ID
50
6
(peak)
(pre-boost),
respectively,
320
110
for
Omicron.
Two
after
boost,
increased
5360
2980,
2670
1930
Following
either
70-80%
of
spike-specific
B
cells
cross-reactive
both
WA1
Significant
equivalent
control
virus
replication
in
lower
airways
was
observed
boost.
Therefore,
an
boost
may
not
provide
greater
protection
compared
a
the
current
vaccine.
New England Journal of Medicine,
Journal Year:
2022,
Volume and Issue:
386(19), P. 1804 - 1816
Published: March 9, 2022
Waning
of
vaccine
protection
against
coronavirus
disease
2019
(Covid-19)
and
the
emergence
omicron
(or
B.1.1.529)
variant
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
have
led
to
expedited
efforts
scale
up
booster
vaccination.
Protection
conferred
by
doses
BNT162b2
(Pfizer–BioNTech)
mRNA-1273
(Moderna)
vaccines
in
Qatar,
as
compared
with
two-dose
primary
series,
is
unclear.
BMC Medicine,
Journal Year:
2022,
Volume and Issue:
20(1)
Published: May 23, 2022
Abstract
Background
It
was
urgent
and
necessary
to
synthesize
the
evidence
for
vaccine
effectiveness
(VE)
against
SARS-CoV-2
variants
of
concern
(VOC).
We
conducted
a
systematic
review
meta-analysis
provide
comprehensive
overview
profile
COVID-19
vaccines
VOC.
Methods
Published
randomized
controlled
trials
(RCTs),
cohort
studies,
case-control
studies
that
evaluated
VE
VOC
(Alpha,
Beta,
Gamma,
Delta,
or
Omicron)
were
searched
until
4
March
2022.
Pooled
estimates
95%
confidence
intervals
(CIs)
calculated
using
random-effects
meta-analysis.
defined
as
(1-estimate).
Results
Eleven
RCTs
(161,388
participants),
20
(52,782,321
26
(2,584,732
cases)
included.
(mRNA-1273,
BNT162b2,
ChAdOx1,
Ad26.COV2.S,
NVX-CoV2373,
BBV152,
CoronaVac,
BBIBP-CorV,
SCB-2019,
CVnCoV,
HB02)
included
in
this
analysis.
Full
vaccination
effective
Alpha,
Omicron
variants,
with
88.0%
(95%
CI,
83.0–91.5),
73.0%
64.3–79.5),
63.0%
47.9–73.7),
77.8%
72.7–82.0),
55.9%
40.9–67.0),
respectively.
Booster
more
Delta
95.5%
94.2–96.5)
80.8%
58.6–91.1),
mRNA
(mRNA-1273/BNT162b2)
seemed
have
higher
over
others;
significant
interactions
(
p
interaction
<
0.10)
observed
between
type
(mRNA
vs.
not
vaccines).
Conclusions
is
highly
Alpha
variant,
moderate
variants.
seem
others.
Science Immunology,
Journal Year:
2022,
Volume and Issue:
7(75)
Published: June 2, 2022
Omicron
is
the
evolutionarily
most
distinct
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
variant
of
concern
(VOC)
to
date.
We
report
that
BA.1
breakthrough
infection
in
BNT162b2-vaccinated
individuals
resulted
strong
neutralizing
activity
against
BA.1,
BA.2,
and
previous
SARS-CoV-2
VOCs
but
not
sublineages
BA.4
BA.5.
induced
a
robust
recall
response,
primarily
expanding
memory
B
(B
JAMA Network Open,
Journal Year:
2023,
Volume and Issue:
6(5), P. e2310650 - e2310650
Published: May 3, 2023
Importance
Estimates
of
the
rate
waning
vaccine
effectiveness
(VE)
against
COVID-19
are
key
to
assess
population
levels
protection
and
future
needs
for
booster
doses
face
resurgence
epidemic
waves.
Objective
To
quantify
progressive
VE
associated
with
Delta
Omicron
variants
SARS-CoV-2
by
number
received
doses.
Data
Sources
PubMed
Web
Science
were
searched
from
databases’
inception
October
19,
2022,
as
well
reference
lists
eligible
articles.
Preprints
included.
Study
Selection
Selected
studies
this
systematic
review
meta-analysis
original
articles
reporting
estimates
over
time
laboratory-confirmed
infection
symptomatic
disease.
Extraction
Synthesis
at
different
points
vaccination
retrieved
studies.
A
secondary
data
analysis
was
performed
project
any
last
dose
administration,
improving
comparability
across
between
2
considered
variants.
Pooled
obtained
random-effects
meta-analysis.
Main
Outcomes
Measures
or
disease
half-life
vaccine-induced
protection.
Results
total
799
149
reviews
published
in
peer-reviewed
journals
35
preprints
identified.
Of
these,
40
included
analysis.
a
primary
cycle
both
lower
than
20%
6
months
administration.
Booster
restored
comparable
those
acquired
soon
after
administration
cycle.
However,
9
30%
The
estimated
be
87
days
(95%
CI,
67-129
days)
compared
316
240-470
Delta.
Similar
rates
found
age
segments
population.
Conclusions
Relevance
These
findings
suggest
that
vaccines
rapidly
wanes
dose.
results
can
inform
design
appropriate
targets
timing
programs.
The Lancet Infectious Diseases,
Journal Year:
2022,
Volume and Issue:
22(8), P. 1131 - 1141
Published: May 9, 2022
Some
high-income
countries
have
deployed
fourth
doses
of
COVID-19
vaccines,
but
the
clinical
need,
effectiveness,
timing,
and
dose
a
remain
uncertain.
We
aimed
to
investigate
safety,
reactogenicity,
immunogenicity
fourth-dose
boosters
against
COVID-19.
